$0.79
-0.09 (-10.36%)
Open$0.86
Previous Close$0.88
Day High$0.86
Day Low$0.79
52W High$5.10
52W Low$0.80
Volume—
Avg Volume102.8K
Market Cap23.17M
P/E Ratio—
EPS$-2.80
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+310.1% upside
Current
$0.79
$0.79
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.32M | 15.18M | 16.45M |
| Net Income | 933.1K | 1.21M | 962.0K |
| Profit Margin | 6.1% | 8.0% | 5.9% |
| EBITDA | 2.07M | 1.98M | 2.22M |
| Free Cash Flow | 922.5K | 1.07M | 1.04M |
| Rev Growth | -6.3% | +1.7% | +13.6% |
| Debt/Equity | 0.26 | 0.33 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |